FibroBiologics reports Q1 net loss roughly ($5M)

The net loss for the three months ended March 31, 2026, was primarily due to research and development expenses and general and administrative expenses. Pete O’Heeron, CEO, and Founder of FibroBiologics (FBLG) commented, “During the first quarter of 2026, we made important progress initiating our phase 1/2 clinical trial, including completing cGMP manufacturing of the first batch of the CYWC628 drug product and site onboarding to support dosing the first patient in the second quarter. We continued to build momentum across our pipeline, with positive preclinical data in both our burn and degenerative disc disease programs, further supporting the potential of our fibroblast-based platform. We also strengthened our cash position with additional capital. As we move into the next phase of execution, our focus is on initiating our clinical study, generating meaningful data, and advancing our pipeline programs in psoriasis and multiple sclerosis.”